-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] As the country vigorously promotes the development of innovative industries, domestic pharmaceutical innovation companies have begun to increase
.
It is worth noting that the research and development of new drugs is not easy.
It has the characteristics of high risk and high investment.
For many companies, the slightest carelessness will lead to waste of investment.
Therefore, in order to reduce R&D investment and improve innovation efficiency, many companies start More and more emphasis on "License in"
.
In this context, more and more new drugs introduced by pharmaceutical companies have also begun to be approved for clinical use and marketed in China
.
On April 21, the NMPA website announced that the new anti-tumor drug Procarbazine Hydrochloride Capsules application submitted by Zhaoke Pharmaceutical, a subsidiary of Li's Pharmaceutical Factory, has been approved
.
According to an earlier press release issued by Lee's Big Pharma, the indication for this product's approved marketing application is: for the treatment of advanced Hodgkin's lymphoma
.
According to public information, procarbazine hydrochloride capsules were originally developed by Roche and have been approved for marketing overseas, and are produced by Leadiant Biosciences (formerly Sigma-Tau)
.
A wholly-owned subsidiary of Lee's Pharma signed a distribution agreement with Leadiant in May 2018 to promote the exclusive launch of procarbazine hydrochloride capsules in Greater China
.
On April 20, the website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China announced that a new class 2.
4 drug named NBTXR3 has obtained an implied license for a clinical trial and is intended to be developed for the treatment of head and neck squamous cell carcinoma.
.
According to public information, NBTXR3 is a novel radio-enhancer developed by Nanobiotix, which is intended for the treatment of tumors.
It consists of functionalized hafnium dioxide (HfO2) nanoparticles, which are administered via a one-time intratumoral injection and activated by radiotherapy.
.
It is understood that in May 2021, Liantuo announced a partnership with Nanobiotix to obtain the exclusive license to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore and Thailand
.
Under the agreement, LianBio will participate in a global Phase 3 head and neck cancer registration study to evaluate the efficacy of NBTXR3 in patients with locally advanced head and neck squamous cell carcinoma (HNSCC)
.
Upfront and potential milestone payments for this collaboration are up to $240 million
.
It has long been the norm in the industry for domestic pharmaceutical companies to improve their innovative drug R&D pipelines by introducing new foreign drugs
.
Due to the characteristics of high R&D investment, high risk, and long payback period in new drug R&D; and in recent years, the state is vigorously promoting pharmaceutical innovation; in order to enhance innovation strength and control R&D costs, more and more domestic pharmaceutical companies are currently in Through the "authorized introduction" model, innovative projects are introduced to accelerate the process of new drug listing, further enrich product lines, and improve competitiveness in innovation
.
In this context, it is obvious that the innovative achievements of pharmaceutical companies in recent years have begun to appear at an accelerated rate, and a large number of new drugs are being approved for clinical trials and listed on the market one after another
.
The industry expects that under the background of increasing support for pharmaceutical innovation at the policy level, the popularity of the innovative drug capital market will continue to rise
.
At the same time, a large number of listed pharmaceutical companies will continue to introduce new drugs to accelerate their innovation capabilities
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
It is worth noting that the research and development of new drugs is not easy.
It has the characteristics of high risk and high investment.
For many companies, the slightest carelessness will lead to waste of investment.
Therefore, in order to reduce R&D investment and improve innovation efficiency, many companies start More and more emphasis on "License in"
.
In this context, more and more new drugs introduced by pharmaceutical companies have also begun to be approved for clinical use and marketed in China
.
On April 21, the NMPA website announced that the new anti-tumor drug Procarbazine Hydrochloride Capsules application submitted by Zhaoke Pharmaceutical, a subsidiary of Li's Pharmaceutical Factory, has been approved
.
According to an earlier press release issued by Lee's Big Pharma, the indication for this product's approved marketing application is: for the treatment of advanced Hodgkin's lymphoma
.
According to public information, procarbazine hydrochloride capsules were originally developed by Roche and have been approved for marketing overseas, and are produced by Leadiant Biosciences (formerly Sigma-Tau)
.
A wholly-owned subsidiary of Lee's Pharma signed a distribution agreement with Leadiant in May 2018 to promote the exclusive launch of procarbazine hydrochloride capsules in Greater China
.
On April 20, the website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China announced that a new class 2.
4 drug named NBTXR3 has obtained an implied license for a clinical trial and is intended to be developed for the treatment of head and neck squamous cell carcinoma.
.
According to public information, NBTXR3 is a novel radio-enhancer developed by Nanobiotix, which is intended for the treatment of tumors.
It consists of functionalized hafnium dioxide (HfO2) nanoparticles, which are administered via a one-time intratumoral injection and activated by radiotherapy.
.
It is understood that in May 2021, Liantuo announced a partnership with Nanobiotix to obtain the exclusive license to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore and Thailand
.
Under the agreement, LianBio will participate in a global Phase 3 head and neck cancer registration study to evaluate the efficacy of NBTXR3 in patients with locally advanced head and neck squamous cell carcinoma (HNSCC)
.
Upfront and potential milestone payments for this collaboration are up to $240 million
.
It has long been the norm in the industry for domestic pharmaceutical companies to improve their innovative drug R&D pipelines by introducing new foreign drugs
.
Due to the characteristics of high R&D investment, high risk, and long payback period in new drug R&D; and in recent years, the state is vigorously promoting pharmaceutical innovation; in order to enhance innovation strength and control R&D costs, more and more domestic pharmaceutical companies are currently in Through the "authorized introduction" model, innovative projects are introduced to accelerate the process of new drug listing, further enrich product lines, and improve competitiveness in innovation
.
In this context, it is obvious that the innovative achievements of pharmaceutical companies in recent years have begun to appear at an accelerated rate, and a large number of new drugs are being approved for clinical trials and listed on the market one after another
.
The industry expects that under the background of increasing support for pharmaceutical innovation at the policy level, the popularity of the innovative drug capital market will continue to rise
.
At the same time, a large number of listed pharmaceutical companies will continue to introduce new drugs to accelerate their innovation capabilities
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
